ovarian adnexal mass
Aspira Q4 Revenues up 36 Percent
The company reported total revenues of $1.9 million, up from $1.4 million in Q4 2020, while sales of its OVA1plus test were up 23 percent.
Aspira Women's Health Preliminary Q4 OVA1 Sales up 23 Percent; Firm Details Pipeline Progess
The company also announced a five-year deal with healthcare group Axia Women's Health to provide in-house genetic carrier screening.
Aspira Q4 Revenues Up 11 Percent, Firm Inks Deal for Ovarian Cancer Detection Tech
The agreement is with the Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Medical University Lodz.
The glycoproteomics firm is using its mass spec platform for ovarian cancer and immunotherapy tests as well as service work for pharma and other partners.
Aspira Eyes $11M in Private Equity Financing
Investors in the company, formerly known as Vermillion, have agreed to purchase $11 million in unregistered common stock at a price of $3.50 per share.